nodes	percent_of_prediction	percent_of_DWPC	metapath
Gliclazide—VEGFA—colon cancer	0.662	1	CbGaD
Gliclazide—ALB—Irinotecan—colon cancer	0.0452	0.258	CbGbCtD
Gliclazide—ALB—Fluorouracil—colon cancer	0.0434	0.247	CbGbCtD
Gliclazide—CYP2C9—Capecitabine—colon cancer	0.0394	0.225	CbGbCtD
Gliclazide—ALB—Methotrexate—colon cancer	0.0239	0.136	CbGbCtD
Gliclazide—CYP2C9—Fluorouracil—colon cancer	0.0234	0.133	CbGbCtD
Gliclazide—Glipizide—PPARG—colon cancer	0.00145	0.697	CrCbGaD
Gliclazide—VEGFA—smooth muscle tissue—colon cancer	0.00063	0.121	CbGeAlD
Gliclazide—ALB—gall bladder—colon cancer	0.000596	0.114	CbGeAlD
Gliclazide—VEGFA—bone marrow—colon cancer	0.000459	0.0879	CbGeAlD
Gliclazide—VEGFA—vagina—colon cancer	0.000439	0.0842	CbGeAlD
Gliclazide—ABCC8—smooth muscle tissue—colon cancer	0.000415	0.0795	CbGeAlD
Gliclazide—ABCC8—renal system—colon cancer	0.0004	0.0766	CbGeAlD
Gliclazide—Chlorpropamide—ABCB1—colon cancer	0.000377	0.181	CrCbGaD
Gliclazide—VEGFA—liver—colon cancer	0.000371	0.071	CbGeAlD
Gliclazide—KCNJ11—lymphoid tissue—colon cancer	0.00036	0.069	CbGeAlD
Gliclazide—VEGFA—lymph node—colon cancer	0.000284	0.0544	CbGeAlD
Gliclazide—VEGFA—Signaling events mediated by TCPTP—EGFR—colon cancer	0.000255	0.0055	CbGpPWpGaD
Gliclazide—Glyburide—ABCB1—colon cancer	0.000254	0.122	CrCbGaD
Gliclazide—VEGFA—Bladder Cancer—HRAS—colon cancer	0.000251	0.00542	CbGpPWpGaD
Gliclazide—VEGFA—Aryl Hydrocarbon Receptor—NRAS—colon cancer	0.00025	0.0054	CbGpPWpGaD
Gliclazide—CYP2C19—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	0.000249	0.00537	CbGpPWpGaD
Gliclazide—CYP2C19—Metapathway biotransformation—CHST5—colon cancer	0.000242	0.00522	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—BUB1B—colon cancer	0.000241	0.0052	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—CA7—colon cancer	0.000239	0.00516	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—DCC—colon cancer	0.000234	0.00506	CbGpPWpGaD
Gliclazide—VEGFA—VEGFR1 specific signals—AKT1—colon cancer	0.000234	0.00504	CbGpPWpGaD
Gliclazide—VEGFA—VEGFR2 mediated cell proliferation—HRAS—colon cancer	0.000233	0.00503	CbGpPWpGaD
Gliclazide—VEGFA—Aryl Hydrocarbon Receptor—MYC—colon cancer	0.000233	0.00503	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—CA7—colon cancer	0.000232	0.005	CbGpPWpGaD
Gliclazide—VEGFA—Aryl Hydrocarbon Receptor—EGFR—colon cancer	0.000228	0.00492	CbGpPWpGaD
Gliclazide—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	0.000227	0.0049	CbGpPWpGaD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—CASP3—colon cancer	0.000226	0.00488	CbGpPWpGaD
Gliclazide—VEGFA—Differentiation Pathway—TGFB1—colon cancer	0.000224	0.00485	CbGpPWpGaD
Gliclazide—VEGFA—Signaling events mediated by TCPTP—PIK3CA—colon cancer	0.000221	0.00477	CbGpPWpGaD
Gliclazide—CYP2C9—Metapathway biotransformation—CHST5—colon cancer	0.00022	0.00476	CbGpPWpGaD
Gliclazide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—colon cancer	0.000216	0.00466	CbGpPWpGaD
Gliclazide—VEGFA—Aryl Hydrocarbon Receptor—KRAS—colon cancer	0.000215	0.00465	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—BAX—colon cancer	0.000215	0.00463	CbGpPWpGaD
Gliclazide—Malaise—Irinotecan—colon cancer	0.000212	0.00194	CcSEcCtD
Gliclazide—Renal failure acute—Methotrexate—colon cancer	0.000211	0.00193	CcSEcCtD
Gliclazide—Leukopenia—Irinotecan—colon cancer	0.00021	0.00192	CcSEcCtD
Gliclazide—VEGFA—Signaling events mediated by VEGFR1 and VEGFR2—CTNNB1—colon cancer	0.00021	0.00454	CbGpPWpGaD
Gliclazide—Upper respiratory tract infection—Capecitabine—colon cancer	0.00021	0.00192	CcSEcCtD
Gliclazide—Convulsion—Vincristine—colon cancer	0.000209	0.00191	CcSEcCtD
Gliclazide—Hypertension—Vincristine—colon cancer	0.000208	0.00191	CcSEcCtD
Gliclazide—Anaemia—Fluorouracil—colon cancer	0.000208	0.0019	CcSEcCtD
Gliclazide—VEGFA—SHP2 signaling—NRAS—colon cancer	0.000208	0.00449	CbGpPWpGaD
Gliclazide—Loss of consciousness—Irinotecan—colon cancer	0.000206	0.00189	CcSEcCtD
Gliclazide—Photosensitivity reaction—Capecitabine—colon cancer	0.000206	0.00189	CcSEcCtD
Gliclazide—Myalgia—Vincristine—colon cancer	0.000205	0.00188	CcSEcCtD
Gliclazide—Weight increased—Capecitabine—colon cancer	0.000205	0.00188	CcSEcCtD
Gliclazide—Visual disturbance—Methotrexate—colon cancer	0.000205	0.00188	CcSEcCtD
Gliclazide—Cough—Irinotecan—colon cancer	0.000205	0.00188	CcSEcCtD
Gliclazide—Hyperglycaemia—Capecitabine—colon cancer	0.000204	0.00186	CcSEcCtD
Gliclazide—KCNJ11—lymph node—colon cancer	0.000203	0.0389	CbGeAlD
Gliclazide—Hypertension—Irinotecan—colon cancer	0.000203	0.00186	CcSEcCtD
Gliclazide—Pneumonia—Capecitabine—colon cancer	0.000202	0.00185	CcSEcCtD
Gliclazide—VEGFA—Integrins in angiogenesis—SRC—colon cancer	0.000202	0.00436	CbGpPWpGaD
Gliclazide—Leukopenia—Fluorouracil—colon cancer	0.000201	0.00184	CcSEcCtD
Gliclazide—Depression—Capecitabine—colon cancer	0.000201	0.00184	CcSEcCtD
Gliclazide—VEGFA—HIF-1-alpha transcription factor network—EP300—colon cancer	0.0002	0.00432	CbGpPWpGaD
Gliclazide—Stevens-Johnson syndrome—Capecitabine—colon cancer	0.000199	0.00183	CcSEcCtD
Gliclazide—Acute coronary syndrome—Capecitabine—colon cancer	0.000198	0.00182	CcSEcCtD
Gliclazide—Cerebrovascular accident—Methotrexate—colon cancer	0.000198	0.00182	CcSEcCtD
Gliclazide—Renal failure—Capecitabine—colon cancer	0.000198	0.00181	CcSEcCtD
Gliclazide—Discomfort—Irinotecan—colon cancer	0.000198	0.00181	CcSEcCtD
Gliclazide—Neuropathy peripheral—Capecitabine—colon cancer	0.000197	0.00181	CcSEcCtD
Gliclazide—Myocardial infarction—Capecitabine—colon cancer	0.000197	0.00181	CcSEcCtD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—SRC—colon cancer	0.000197	0.00426	CbGpPWpGaD
Gliclazide—Jaundice—Capecitabine—colon cancer	0.000196	0.00179	CcSEcCtD
Gliclazide—Infection—Vincristine—colon cancer	0.000196	0.00179	CcSEcCtD
Gliclazide—Urinary tract infection—Capecitabine—colon cancer	0.000196	0.00179	CcSEcCtD
Gliclazide—Conjunctivitis—Capecitabine—colon cancer	0.000196	0.00179	CcSEcCtD
Gliclazide—Convulsion—Fluorouracil—colon cancer	0.000195	0.00178	CcSEcCtD
Gliclazide—Osteoarthritis—Methotrexate—colon cancer	0.000194	0.00178	CcSEcCtD
Gliclazide—VEGFA—Allograft Rejection—CASP3—colon cancer	0.000193	0.00418	CbGpPWpGaD
Gliclazide—Confusional state—Irinotecan—colon cancer	0.000193	0.00177	CcSEcCtD
Gliclazide—Nervous system disorder—Vincristine—colon cancer	0.000193	0.00177	CcSEcCtD
Gliclazide—Thrombocytopenia—Vincristine—colon cancer	0.000193	0.00176	CcSEcCtD
Gliclazide—Chest pain—Fluorouracil—colon cancer	0.000192	0.00175	CcSEcCtD
Gliclazide—Myalgia—Fluorouracil—colon cancer	0.000192	0.00175	CcSEcCtD
Gliclazide—Infection—Irinotecan—colon cancer	0.00019	0.00174	CcSEcCtD
Gliclazide—Hyperhidrosis—Vincristine—colon cancer	0.00019	0.00174	CcSEcCtD
Gliclazide—Hepatobiliary disease—Capecitabine—colon cancer	0.00019	0.00174	CcSEcCtD
Gliclazide—VEGFA—Signaling events mediated by VEGFR1 and VEGFR2—SRC—colon cancer	0.00019	0.00411	CbGpPWpGaD
Gliclazide—Epistaxis—Capecitabine—colon cancer	0.00019	0.00174	CcSEcCtD
Gliclazide—Discomfort—Fluorouracil—colon cancer	0.000189	0.00173	CcSEcCtD
Gliclazide—VEGFA—SHP2 signaling—EGFR—colon cancer	0.000189	0.00409	CbGpPWpGaD
Gliclazide—CYP2C19—digestive system—colon cancer	0.000189	0.0362	CbGeAlD
Gliclazide—Nervous system disorder—Irinotecan—colon cancer	0.000188	0.00172	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—ABCB1—colon cancer	0.000188	0.00406	CbGpPWpGaD
Gliclazide—Agranulocytosis—Capecitabine—colon cancer	0.000188	0.00172	CcSEcCtD
Gliclazide—Thrombocytopenia—Irinotecan—colon cancer	0.000188	0.00172	CcSEcCtD
Gliclazide—Hyperhidrosis—Irinotecan—colon cancer	0.000185	0.0017	CcSEcCtD
Gliclazide—Confusional state—Fluorouracil—colon cancer	0.000185	0.00169	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—TYMS—colon cancer	0.000185	0.00399	CbGpPWpGaD
Gliclazide—Hypotension—Vincristine—colon cancer	0.000184	0.00168	CcSEcCtD
Gliclazide—Bradycardia—Capecitabine—colon cancer	0.000184	0.00168	CcSEcCtD
Gliclazide—ABCC8—FOXA2 and FOXA3 transcription factor networks—AKT1—colon cancer	0.000183	0.00396	CbGpPWpGaD
Gliclazide—VEGFA—Aryl Hydrocarbon Receptor—HRAS—colon cancer	0.000183	0.00395	CbGpPWpGaD
Gliclazide—Infection—Fluorouracil—colon cancer	0.000182	0.00167	CcSEcCtD
Gliclazide—Rhinitis—Capecitabine—colon cancer	0.000181	0.00166	CcSEcCtD
Gliclazide—Hepatitis—Capecitabine—colon cancer	0.000181	0.00165	CcSEcCtD
Gliclazide—Nervous system disorder—Fluorouracil—colon cancer	0.00018	0.00165	CcSEcCtD
Gliclazide—Thrombocytopenia—Fluorouracil—colon cancer	0.00018	0.00165	CcSEcCtD
Gliclazide—Hypoaesthesia—Capecitabine—colon cancer	0.00018	0.00164	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Vincristine—colon cancer	0.000179	0.00164	CcSEcCtD
Gliclazide—Pharyngitis—Capecitabine—colon cancer	0.000179	0.00164	CcSEcCtD
Gliclazide—Tachycardia—Fluorouracil—colon cancer	0.000179	0.00164	CcSEcCtD
Gliclazide—Hypotension—Irinotecan—colon cancer	0.000179	0.00164	CcSEcCtD
Gliclazide—VEGFA—SHP2 signaling—KRAS—colon cancer	0.000179	0.00386	CbGpPWpGaD
Gliclazide—VEGFA—Endochondral Ossification—TGFB1—colon cancer	0.000178	0.00385	CbGpPWpGaD
Gliclazide—Insomnia—Vincristine—colon cancer	0.000178	0.00163	CcSEcCtD
Gliclazide—Oedema peripheral—Capecitabine—colon cancer	0.000178	0.00163	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—BAX—colon cancer	0.000178	0.00384	CbGpPWpGaD
Gliclazide—KCNJ11—FOXA2 and FOXA3 transcription factor networks—AKT1—colon cancer	0.000178	0.00384	CbGpPWpGaD
Gliclazide—Paraesthesia—Vincristine—colon cancer	0.000177	0.00162	CcSEcCtD
Gliclazide—Toxic epidermal necrolysis—Methotrexate—colon cancer	0.000175	0.0016	CcSEcCtD
Gliclazide—ALB—liver—colon cancer	0.000175	0.0335	CbGeAlD
Gliclazide—Visual impairment—Capecitabine—colon cancer	0.000174	0.00159	CcSEcCtD
Gliclazide—Insomnia—Irinotecan—colon cancer	0.000173	0.00159	CcSEcCtD
Gliclazide—Paraesthesia—Irinotecan—colon cancer	0.000172	0.00158	CcSEcCtD
Gliclazide—Hypotension—Fluorouracil—colon cancer	0.000172	0.00157	CcSEcCtD
Gliclazide—Dyspnoea—Irinotecan—colon cancer	0.000171	0.00156	CcSEcCtD
Gliclazide—Erythema multiforme—Capecitabine—colon cancer	0.000171	0.00156	CcSEcCtD
Gliclazide—Somnolence—Irinotecan—colon cancer	0.00017	0.00156	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Vincristine—colon cancer	0.00017	0.00156	CcSEcCtD
Gliclazide—Fatigue—Vincristine—colon cancer	0.00017	0.00155	CcSEcCtD
Gliclazide—Eye disorder—Capecitabine—colon cancer	0.000169	0.00154	CcSEcCtD
Gliclazide—Dyspepsia—Irinotecan—colon cancer	0.000169	0.00154	CcSEcCtD
Gliclazide—Tinnitus—Capecitabine—colon cancer	0.000168	0.00154	CcSEcCtD
Gliclazide—Pain—Vincristine—colon cancer	0.000168	0.00154	CcSEcCtD
Gliclazide—Constipation—Vincristine—colon cancer	0.000168	0.00154	CcSEcCtD
Gliclazide—Asthma—Methotrexate—colon cancer	0.000168	0.00154	CcSEcCtD
Gliclazide—Flushing—Capecitabine—colon cancer	0.000168	0.00153	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.000167	0.00153	CcSEcCtD
Gliclazide—VEGFA—Developmental Biology—DCC—colon cancer	0.000167	0.00361	CbGpPWpGaD
Gliclazide—CYP2C19—vagina—colon cancer	0.000167	0.032	CbGeAlD
Gliclazide—Insomnia—Fluorouracil—colon cancer	0.000166	0.00152	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Irinotecan—colon cancer	0.000166	0.00151	CcSEcCtD
Gliclazide—Fatigue—Irinotecan—colon cancer	0.000165	0.00151	CcSEcCtD
Gliclazide—Paraesthesia—Fluorouracil—colon cancer	0.000165	0.00151	CcSEcCtD
Gliclazide—VEGFA—SHP2 signaling—PIK3CA—colon cancer	0.000164	0.00355	CbGpPWpGaD
Gliclazide—Constipation—Irinotecan—colon cancer	0.000164	0.0015	CcSEcCtD
Gliclazide—Pain—Irinotecan—colon cancer	0.000164	0.0015	CcSEcCtD
Gliclazide—Dyspnoea—Fluorouracil—colon cancer	0.000164	0.0015	CcSEcCtD
Gliclazide—Somnolence—Fluorouracil—colon cancer	0.000163	0.00149	CcSEcCtD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—KRAS—colon cancer	0.000163	0.00352	CbGpPWpGaD
Gliclazide—Chills—Capecitabine—colon cancer	0.000162	0.00148	CcSEcCtD
Gliclazide—Dyspepsia—Fluorouracil—colon cancer	0.000162	0.00148	CcSEcCtD
Gliclazide—Arrhythmia—Capecitabine—colon cancer	0.000161	0.00148	CcSEcCtD
Gliclazide—Abdominal discomfort—Methotrexate—colon cancer	0.000161	0.00147	CcSEcCtD
Gliclazide—Gastrointestinal pain—Vincristine—colon cancer	0.000161	0.00147	CcSEcCtD
Gliclazide—Pancytopenia—Methotrexate—colon cancer	0.00016	0.00146	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000159	0.00145	CcSEcCtD
Gliclazide—Mental disorder—Capecitabine—colon cancer	0.000158	0.00145	CcSEcCtD
Gliclazide—Feeling abnormal—Irinotecan—colon cancer	0.000158	0.00145	CcSEcCtD
Gliclazide—Erythema—Capecitabine—colon cancer	0.000157	0.00144	CcSEcCtD
Gliclazide—Malnutrition—Capecitabine—colon cancer	0.000157	0.00144	CcSEcCtD
Gliclazide—Pain—Fluorouracil—colon cancer	0.000157	0.00144	CcSEcCtD
Gliclazide—Gastrointestinal pain—Irinotecan—colon cancer	0.000157	0.00143	CcSEcCtD
Gliclazide—Upper respiratory tract infection—Methotrexate—colon cancer	0.000156	0.00143	CcSEcCtD
Gliclazide—Abdominal pain—Vincristine—colon cancer	0.000156	0.00142	CcSEcCtD
Gliclazide—Body temperature increased—Vincristine—colon cancer	0.000156	0.00142	CcSEcCtD
Gliclazide—Flatulence—Capecitabine—colon cancer	0.000155	0.00142	CcSEcCtD
Gliclazide—Erectile dysfunction—Methotrexate—colon cancer	0.000155	0.00142	CcSEcCtD
Gliclazide—VEGFA—Integrins in angiogenesis—PIK3CA—colon cancer	0.000154	0.00332	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—BRAF—colon cancer	0.000154	0.00332	CbGpPWpGaD
Gliclazide—Photosensitivity reaction—Methotrexate—colon cancer	0.000153	0.0014	CcSEcCtD
Gliclazide—Back pain—Capecitabine—colon cancer	0.000152	0.00139	CcSEcCtD
Gliclazide—VEGFA—SHP2 signaling—HRAS—colon cancer	0.000152	0.00328	CbGpPWpGaD
Gliclazide—Abdominal pain—Irinotecan—colon cancer	0.000152	0.00139	CcSEcCtD
Gliclazide—Body temperature increased—Irinotecan—colon cancer	0.000152	0.00139	CcSEcCtD
Gliclazide—Feeling abnormal—Fluorouracil—colon cancer	0.000151	0.00138	CcSEcCtD
Gliclazide—VEGFA—Allograft Rejection—TGFB1—colon cancer	0.000151	0.00325	CbGpPWpGaD
Gliclazide—Pneumonia—Methotrexate—colon cancer	0.000151	0.00138	CcSEcCtD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—CDH1—colon cancer	0.00015	0.00325	CbGpPWpGaD
Gliclazide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	0.00015	0.00325	CbGpPWpGaD
Gliclazide—Drowsiness—Methotrexate—colon cancer	0.00015	0.00137	CcSEcCtD
Gliclazide—Depression—Methotrexate—colon cancer	0.000149	0.00137	CcSEcCtD
Gliclazide—VEGFA—Platelet degranulation—TGFB1—colon cancer	0.000149	0.00322	CbGpPWpGaD
Gliclazide—Stevens-Johnson syndrome—Methotrexate—colon cancer	0.000149	0.00136	CcSEcCtD
Gliclazide—Tremor—Capecitabine—colon cancer	0.000147	0.00135	CcSEcCtD
Gliclazide—Renal failure—Methotrexate—colon cancer	0.000147	0.00135	CcSEcCtD
Gliclazide—VEGFA—EPH-Ephrin signaling—SRC—colon cancer	0.000147	0.00317	CbGpPWpGaD
Gliclazide—CYP2C9—digestive system—colon cancer	0.000146	0.0281	CbGeAlD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—CTNNB1—colon cancer	0.000146	0.00316	CbGpPWpGaD
Gliclazide—Ill-defined disorder—Capecitabine—colon cancer	0.000146	0.00134	CcSEcCtD
Gliclazide—Urticaria—Fluorouracil—colon cancer	0.000146	0.00134	CcSEcCtD
Gliclazide—Conjunctivitis—Methotrexate—colon cancer	0.000146	0.00133	CcSEcCtD
Gliclazide—Anaemia—Capecitabine—colon cancer	0.000145	0.00133	CcSEcCtD
Gliclazide—Body temperature increased—Fluorouracil—colon cancer	0.000145	0.00133	CcSEcCtD
Gliclazide—Hypersensitivity—Vincristine—colon cancer	0.000145	0.00133	CcSEcCtD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—TP53—colon cancer	0.000145	0.00313	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—CHST5—colon cancer	0.000145	0.00313	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—ODC1—colon cancer	0.000145	0.00313	CbGpPWpGaD
Gliclazide—VEGFA—Signaling events mediated by VEGFR1 and VEGFR2—PIK3CA—colon cancer	0.000145	0.00312	CbGpPWpGaD
Gliclazide—Sweating—Methotrexate—colon cancer	0.000144	0.00131	CcSEcCtD
Gliclazide—VEGFA—Response to elevated platelet cytosolic Ca2+—TGFB1—colon cancer	0.000142	0.00307	CbGpPWpGaD
Gliclazide—Malaise—Capecitabine—colon cancer	0.000142	0.0013	CcSEcCtD
Gliclazide—Hepatobiliary disease—Methotrexate—colon cancer	0.000142	0.0013	CcSEcCtD
Gliclazide—Epistaxis—Methotrexate—colon cancer	0.000141	0.00129	CcSEcCtD
Gliclazide—Hypersensitivity—Irinotecan—colon cancer	0.000141	0.00129	CcSEcCtD
Gliclazide—Asthenia—Vincristine—colon cancer	0.000141	0.00129	CcSEcCtD
Gliclazide—VEGFA—Developmental Biology—HNF4A—colon cancer	0.000141	0.00304	CbGpPWpGaD
Gliclazide—CYP2C19—liver—colon cancer	0.000141	0.027	CbGeAlD
Gliclazide—Leukopenia—Capecitabine—colon cancer	0.000141	0.00129	CcSEcCtD
Gliclazide—KCNJ11—Metabolism—CHST5—colon cancer	0.00014	0.00303	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—ODC1—colon cancer	0.00014	0.00303	CbGpPWpGaD
Gliclazide—Agranulocytosis—Methotrexate—colon cancer	0.00014	0.00128	CcSEcCtD
Gliclazide—Palpitations—Capecitabine—colon cancer	0.000139	0.00127	CcSEcCtD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—HRAS—colon cancer	0.000139	0.003	CbGpPWpGaD
Gliclazide—Loss of consciousness—Capecitabine—colon cancer	0.000138	0.00126	CcSEcCtD
Gliclazide—VEGFA—Signaling by VEGF—CTNNB1—colon cancer	0.000138	0.00298	CbGpPWpGaD
Gliclazide—Asthenia—Irinotecan—colon cancer	0.000138	0.00126	CcSEcCtD
Gliclazide—Cough—Capecitabine—colon cancer	0.000137	0.00126	CcSEcCtD
Gliclazide—Hypertension—Capecitabine—colon cancer	0.000136	0.00124	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—APC—colon cancer	0.000135	0.00293	CbGpPWpGaD
Gliclazide—Hypersensitivity—Fluorouracil—colon cancer	0.000135	0.00124	CcSEcCtD
Gliclazide—Diarrhoea—Vincristine—colon cancer	0.000135	0.00123	CcSEcCtD
Gliclazide—Hepatitis—Methotrexate—colon cancer	0.000134	0.00123	CcSEcCtD
Gliclazide—ALB—lymph node—colon cancer	0.000134	0.0257	CbGeAlD
Gliclazide—Myalgia—Capecitabine—colon cancer	0.000134	0.00123	CcSEcCtD
Gliclazide—Arthralgia—Capecitabine—colon cancer	0.000134	0.00123	CcSEcCtD
Gliclazide—Chest pain—Capecitabine—colon cancer	0.000134	0.00123	CcSEcCtD
Gliclazide—Pharyngitis—Methotrexate—colon cancer	0.000133	0.00122	CcSEcCtD
Gliclazide—Anxiety—Capecitabine—colon cancer	0.000133	0.00122	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000133	0.00122	CcSEcCtD
Gliclazide—Discomfort—Capecitabine—colon cancer	0.000132	0.00121	CcSEcCtD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—SRC—colon cancer	0.000132	0.00286	CbGpPWpGaD
Gliclazide—Diarrhoea—Irinotecan—colon cancer	0.000131	0.0012	CcSEcCtD
Gliclazide—Dry mouth—Capecitabine—colon cancer	0.000131	0.0012	CcSEcCtD
Gliclazide—Dizziness—Vincristine—colon cancer	0.00013	0.00119	CcSEcCtD
Gliclazide—Pruritus—Fluorouracil—colon cancer	0.00013	0.00119	CcSEcCtD
Gliclazide—Visual impairment—Methotrexate—colon cancer	0.00013	0.00119	CcSEcCtD
Gliclazide—Confusional state—Capecitabine—colon cancer	0.000129	0.00118	CcSEcCtD
Gliclazide—VEGFA—Focal Adhesion—BRAF—colon cancer	0.000128	0.00276	CbGpPWpGaD
Gliclazide—Infection—Capecitabine—colon cancer	0.000127	0.00117	CcSEcCtD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—NRAS—colon cancer	0.000127	0.00275	CbGpPWpGaD
Gliclazide—Erythema multiforme—Methotrexate—colon cancer	0.000127	0.00116	CcSEcCtD
Gliclazide—Dizziness—Irinotecan—colon cancer	0.000127	0.00116	CcSEcCtD
Gliclazide—Nervous system disorder—Capecitabine—colon cancer	0.000126	0.00115	CcSEcCtD
Gliclazide—Eye disorder—Methotrexate—colon cancer	0.000126	0.00115	CcSEcCtD
Gliclazide—Diarrhoea—Fluorouracil—colon cancer	0.000126	0.00115	CcSEcCtD
Gliclazide—Thrombocytopenia—Capecitabine—colon cancer	0.000126	0.00115	CcSEcCtD
Gliclazide—VEGFA—Integrins in angiogenesis—AKT1—colon cancer	0.000126	0.00271	CbGpPWpGaD
Gliclazide—Tinnitus—Methotrexate—colon cancer	0.000125	0.00115	CcSEcCtD
Gliclazide—Tachycardia—Capecitabine—colon cancer	0.000125	0.00115	CcSEcCtD
Gliclazide—Vomiting—Vincristine—colon cancer	0.000125	0.00115	CcSEcCtD
Gliclazide—VEGFA—Signaling by VEGF—SRC—colon cancer	0.000125	0.0027	CbGpPWpGaD
Gliclazide—Skin disorder—Capecitabine—colon cancer	0.000125	0.00114	CcSEcCtD
Gliclazide—Rash—Vincristine—colon cancer	0.000124	0.00114	CcSEcCtD
Gliclazide—Hyperhidrosis—Capecitabine—colon cancer	0.000124	0.00114	CcSEcCtD
Gliclazide—Dermatitis—Vincristine—colon cancer	0.000124	0.00114	CcSEcCtD
Gliclazide—VEGFA—Endochondral Ossification—AKT1—colon cancer	0.000124	0.00268	CbGpPWpGaD
Gliclazide—Headache—Vincristine—colon cancer	0.000123	0.00113	CcSEcCtD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—AKT1—colon cancer	0.000122	0.00264	CbGpPWpGaD
Gliclazide—Vomiting—Irinotecan—colon cancer	0.000122	0.00112	CcSEcCtD
Gliclazide—Dizziness—Fluorouracil—colon cancer	0.000121	0.00111	CcSEcCtD
Gliclazide—VEGFA—HIF-1-alpha transcription factor network—AKT1—colon cancer	0.000121	0.00261	CbGpPWpGaD
Gliclazide—Rash—Irinotecan—colon cancer	0.000121	0.00111	CcSEcCtD
Gliclazide—Dermatitis—Irinotecan—colon cancer	0.000121	0.00111	CcSEcCtD
Gliclazide—Chills—Methotrexate—colon cancer	0.000121	0.0011	CcSEcCtD
Gliclazide—Headache—Irinotecan—colon cancer	0.00012	0.0011	CcSEcCtD
Gliclazide—VEGFA—Signaling by VEGF—NRAS—colon cancer	0.00012	0.00259	CbGpPWpGaD
Gliclazide—Hypotension—Capecitabine—colon cancer	0.00012	0.0011	CcSEcCtD
Gliclazide—VEGFA—Signaling events mediated by VEGFR1 and VEGFR2—AKT1—colon cancer	0.000118	0.00255	CbGpPWpGaD
Gliclazide—Mental disorder—Methotrexate—colon cancer	0.000118	0.00108	CcSEcCtD
Gliclazide—VEGFA—Signaling Pathways—DLC1—colon cancer	0.000118	0.00254	CbGpPWpGaD
Gliclazide—Malnutrition—Methotrexate—colon cancer	0.000117	0.00107	CcSEcCtD
Gliclazide—Erythema—Methotrexate—colon cancer	0.000117	0.00107	CcSEcCtD
Gliclazide—Nausea—Vincristine—colon cancer	0.000117	0.00107	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Capecitabine—colon cancer	0.000117	0.00107	CcSEcCtD
Gliclazide—Vomiting—Fluorouracil—colon cancer	0.000117	0.00107	CcSEcCtD
Gliclazide—Insomnia—Capecitabine—colon cancer	0.000116	0.00106	CcSEcCtD
Gliclazide—Rash—Fluorouracil—colon cancer	0.000116	0.00106	CcSEcCtD
Gliclazide—Dermatitis—Fluorouracil—colon cancer	0.000116	0.00106	CcSEcCtD
Gliclazide—Paraesthesia—Capecitabine—colon cancer	0.000115	0.00105	CcSEcCtD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—CASP3—colon cancer	0.000115	0.00249	CbGpPWpGaD
Gliclazide—Headache—Fluorouracil—colon cancer	0.000115	0.00105	CcSEcCtD
Gliclazide—Dyspnoea—Capecitabine—colon cancer	0.000114	0.00105	CcSEcCtD
Gliclazide—Nausea—Irinotecan—colon cancer	0.000114	0.00104	CcSEcCtD
Gliclazide—Back pain—Methotrexate—colon cancer	0.000113	0.00104	CcSEcCtD
Gliclazide—Dyspepsia—Capecitabine—colon cancer	0.000113	0.00103	CcSEcCtD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—CASP3—colon cancer	0.000112	0.00242	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—CCND1—colon cancer	0.000112	0.00242	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—CTNNB1—colon cancer	0.000111	0.0024	CbGpPWpGaD
Gliclazide—Gastrointestinal disorder—Capecitabine—colon cancer	0.000111	0.00101	CcSEcCtD
Gliclazide—Fatigue—Capecitabine—colon cancer	0.000111	0.00101	CcSEcCtD
Gliclazide—VEGFA—Signaling Pathways—LGR5—colon cancer	0.000111	0.00239	CbGpPWpGaD
Gliclazide—Constipation—Capecitabine—colon cancer	0.00011	0.001	CcSEcCtD
Gliclazide—Pain—Capecitabine—colon cancer	0.00011	0.001	CcSEcCtD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—KRAS—colon cancer	0.000109	0.00237	CbGpPWpGaD
Gliclazide—CYP2C9—liver—colon cancer	0.000109	0.0209	CbGeAlD
Gliclazide—Nausea—Fluorouracil—colon cancer	0.000109	0.000998	CcSEcCtD
Gliclazide—Ill-defined disorder—Methotrexate—colon cancer	0.000109	0.000994	CcSEcCtD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—CTNNB1—colon cancer	0.000108	0.00234	CbGpPWpGaD
Gliclazide—Anaemia—Methotrexate—colon cancer	0.000108	0.00099	CcSEcCtD
Gliclazide—Feeling abnormal—Capecitabine—colon cancer	0.000106	0.000968	CcSEcCtD
Gliclazide—Malaise—Methotrexate—colon cancer	0.000106	0.000966	CcSEcCtD
Gliclazide—Gastrointestinal pain—Capecitabine—colon cancer	0.000105	0.00096	CcSEcCtD
Gliclazide—Leukopenia—Methotrexate—colon cancer	0.000105	0.000959	CcSEcCtD
Gliclazide—VEGFA—Signaling by VEGF—KRAS—colon cancer	0.000103	0.00223	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—EP300—colon cancer	0.000103	0.00223	CbGpPWpGaD
Gliclazide—VEGFA—EPH-Ephrin signaling—HRAS—colon cancer	0.000103	0.00223	CbGpPWpGaD
Gliclazide—ABCC8—Neuronal System—BRAF—colon cancer	0.000103	0.00222	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—PTGS2—colon cancer	0.000103	0.00222	CbGpPWpGaD
Gliclazide—Cough—Methotrexate—colon cancer	0.000102	0.000935	CcSEcCtD
Gliclazide—Urticaria—Capecitabine—colon cancer	0.000102	0.000933	CcSEcCtD
Gliclazide—Body temperature increased—Capecitabine—colon cancer	0.000101	0.000928	CcSEcCtD
Gliclazide—Abdominal pain—Capecitabine—colon cancer	0.000101	0.000928	CcSEcCtD
Gliclazide—Convulsion—Methotrexate—colon cancer	0.000101	0.000928	CcSEcCtD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—PIK3CA—colon cancer	0.000101	0.00217	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—EP300—colon cancer	0.000101	0.00217	CbGpPWpGaD
Gliclazide—KCNJ11—Neuronal System—BRAF—colon cancer	9.98e-05	0.00216	CbGpPWpGaD
Gliclazide—Arthralgia—Methotrexate—colon cancer	9.97e-05	0.000912	CcSEcCtD
Gliclazide—Myalgia—Methotrexate—colon cancer	9.97e-05	0.000912	CcSEcCtD
Gliclazide—Chest pain—Methotrexate—colon cancer	9.97e-05	0.000912	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	9.9e-05	0.000906	CcSEcCtD
Gliclazide—Discomfort—Methotrexate—colon cancer	9.85e-05	0.000901	CcSEcCtD
Gliclazide—Confusional state—Methotrexate—colon cancer	9.63e-05	0.000882	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	9.55e-05	0.00206	CbGpPWpGaD
Gliclazide—CYP2C19—Arachidonic acid metabolism—PTGS2—colon cancer	9.52e-05	0.00206	CbGpPWpGaD
Gliclazide—VEGFA—Signaling by VEGF—PIK3CA—colon cancer	9.49e-05	0.00205	CbGpPWpGaD
Gliclazide—Infection—Methotrexate—colon cancer	9.49e-05	0.000869	CcSEcCtD
Gliclazide—Hypersensitivity—Capecitabine—colon cancer	9.45e-05	0.000865	CcSEcCtD
Gliclazide—Nervous system disorder—Methotrexate—colon cancer	9.37e-05	0.000857	CcSEcCtD
Gliclazide—Thrombocytopenia—Methotrexate—colon cancer	9.35e-05	0.000856	CcSEcCtD
Gliclazide—VEGFA—Focal Adhesion—CCND1—colon cancer	9.33e-05	0.00202	CbGpPWpGaD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—HRAS—colon cancer	9.31e-05	0.00201	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	9.29e-05	0.00201	CbGpPWpGaD
Gliclazide—Skin disorder—Methotrexate—colon cancer	9.28e-05	0.000849	CcSEcCtD
Gliclazide—VEGFA—Focal Adhesion—CTNNB1—colon cancer	9.24e-05	0.002	CbGpPWpGaD
Gliclazide—Hyperhidrosis—Methotrexate—colon cancer	9.24e-05	0.000845	CcSEcCtD
Gliclazide—Asthenia—Capecitabine—colon cancer	9.21e-05	0.000843	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	9.2e-05	0.00199	CbGpPWpGaD
Gliclazide—Pruritus—Capecitabine—colon cancer	9.08e-05	0.000831	CcSEcCtD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—MYC—colon cancer	8.99e-05	0.00194	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	8.99e-05	0.00194	CbGpPWpGaD
Gliclazide—Hypotension—Methotrexate—colon cancer	8.93e-05	0.000817	CcSEcCtD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—EGFR—colon cancer	8.8e-05	0.0019	CbGpPWpGaD
Gliclazide—VEGFA—Signaling by VEGF—HRAS—colon cancer	8.78e-05	0.0019	CbGpPWpGaD
Gliclazide—Diarrhoea—Capecitabine—colon cancer	8.78e-05	0.000804	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Methotrexate—colon cancer	8.7e-05	0.000797	CcSEcCtD
Gliclazide—CYP2C9—Arachidonic acid metabolism—PTGS2—colon cancer	8.68e-05	0.00188	CbGpPWpGaD
Gliclazide—Insomnia—Methotrexate—colon cancer	8.64e-05	0.000791	CcSEcCtD
Gliclazide—Paraesthesia—Methotrexate—colon cancer	8.58e-05	0.000785	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	8.55e-05	0.00185	CbGpPWpGaD
Gliclazide—Dyspnoea—Methotrexate—colon cancer	8.52e-05	0.000779	CcSEcCtD
Gliclazide—Somnolence—Methotrexate—colon cancer	8.49e-05	0.000777	CcSEcCtD
Gliclazide—Dizziness—Capecitabine—colon cancer	8.49e-05	0.000777	CcSEcCtD
Gliclazide—Dyspepsia—Methotrexate—colon cancer	8.41e-05	0.00077	CcSEcCtD
Gliclazide—VEGFA—Focal Adhesion—SRC—colon cancer	8.35e-05	0.0018	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	8.32e-05	0.0018	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—KRAS—colon cancer	8.31e-05	0.0018	CbGpPWpGaD
Gliclazide—Gastrointestinal disorder—Methotrexate—colon cancer	8.25e-05	0.000755	CcSEcCtD
Gliclazide—Fatigue—Methotrexate—colon cancer	8.24e-05	0.000754	CcSEcCtD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—AKT1—colon cancer	8.22e-05	0.00178	CbGpPWpGaD
Gliclazide—Pain—Methotrexate—colon cancer	8.17e-05	0.000748	CcSEcCtD
Gliclazide—ABCC8—Transmembrane transport of small molecules—ABCB1—colon cancer	8.17e-05	0.00176	CbGpPWpGaD
Gliclazide—Vomiting—Capecitabine—colon cancer	8.16e-05	0.000747	CcSEcCtD
Gliclazide—Rash—Capecitabine—colon cancer	8.09e-05	0.000741	CcSEcCtD
Gliclazide—Dermatitis—Capecitabine—colon cancer	8.08e-05	0.00074	CcSEcCtD
Gliclazide—Headache—Capecitabine—colon cancer	8.04e-05	0.000736	CcSEcCtD
Gliclazide—VEGFA—Signaling Pathways—AXIN2—colon cancer	7.94e-05	0.00172	CbGpPWpGaD
Gliclazide—Feeling abnormal—Methotrexate—colon cancer	7.87e-05	0.00072	CcSEcCtD
Gliclazide—Gastrointestinal pain—Methotrexate—colon cancer	7.81e-05	0.000715	CcSEcCtD
Gliclazide—VEGFA—Signaling by VEGF—AKT1—colon cancer	7.76e-05	0.00168	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CA7—colon cancer	7.7e-05	0.00166	CbGpPWpGaD
Gliclazide—Nausea—Capecitabine—colon cancer	7.62e-05	0.000698	CcSEcCtD
Gliclazide—Urticaria—Methotrexate—colon cancer	7.59e-05	0.000695	CcSEcCtD
Gliclazide—Body temperature increased—Methotrexate—colon cancer	7.55e-05	0.000691	CcSEcCtD
Gliclazide—Abdominal pain—Methotrexate—colon cancer	7.55e-05	0.000691	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	7.45e-05	0.00161	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	7.44e-05	0.00161	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—SRC—colon cancer	7.4e-05	0.0016	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—TP53—colon cancer	7.39e-05	0.0016	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—EGFR—colon cancer	7.32e-05	0.00158	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	7.29e-05	0.00157	CbGpPWpGaD
Gliclazide—Hypersensitivity—Methotrexate—colon cancer	7.04e-05	0.000644	CcSEcCtD
Gliclazide—VEGFA—Cellular responses to stress—CDKN1A—colon cancer	6.94e-05	0.0015	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CA7—colon cancer	6.91e-05	0.00149	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	6.89e-05	0.00149	CbGpPWpGaD
Gliclazide—Asthenia—Methotrexate—colon cancer	6.85e-05	0.000627	CcSEcCtD
Gliclazide—Pruritus—Methotrexate—colon cancer	6.76e-05	0.000619	CcSEcCtD
Gliclazide—ALB—Selenium Micronutrient Network—PTGS2—colon cancer	6.75e-05	0.00146	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—TGFB1—colon cancer	6.62e-05	0.00143	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—EP300—colon cancer	6.6e-05	0.00143	CbGpPWpGaD
Gliclazide—Diarrhoea—Methotrexate—colon cancer	6.54e-05	0.000598	CcSEcCtD
Gliclazide—VEGFA—Focal Adhesion—PIK3CA—colon cancer	6.35e-05	0.00137	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	6.33e-05	0.00137	CbGpPWpGaD
Gliclazide—Dizziness—Methotrexate—colon cancer	6.32e-05	0.000578	CcSEcCtD
Gliclazide—CYP2C9—Metabolism—CA7—colon cancer	6.3e-05	0.00136	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—AKT1—colon cancer	6.24e-05	0.00135	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	6.12e-05	0.00132	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—PPARG—colon cancer	6.11e-05	0.00132	CbGpPWpGaD
Gliclazide—Vomiting—Methotrexate—colon cancer	6.07e-05	0.000556	CcSEcCtD
Gliclazide—Rash—Methotrexate—colon cancer	6.02e-05	0.000551	CcSEcCtD
Gliclazide—Dermatitis—Methotrexate—colon cancer	6.02e-05	0.000551	CcSEcCtD
Gliclazide—Headache—Methotrexate—colon cancer	5.98e-05	0.000548	CcSEcCtD
Gliclazide—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—colon cancer	5.9e-05	0.00128	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—HRAS—colon cancer	5.88e-05	0.00127	CbGpPWpGaD
Gliclazide—ALB—Platelet degranulation—VEGFA—colon cancer	5.74e-05	0.00124	CbGpPWpGaD
Gliclazide—Nausea—Methotrexate—colon cancer	5.67e-05	0.000519	CcSEcCtD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—PIK3CA—colon cancer	5.63e-05	0.00122	CbGpPWpGaD
Gliclazide—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—colon cancer	5.46e-05	0.00118	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—SRC—colon cancer	5.45e-05	0.00118	CbGpPWpGaD
Gliclazide—ALB—Platelet degranulation—TGFB1—colon cancer	5.26e-05	0.00114	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—NRAS—colon cancer	5.24e-05	0.00113	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—AKT1—colon cancer	5.19e-05	0.00112	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	5.17e-05	0.00112	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—TP53—colon cancer	5.05e-05	0.00109	CbGpPWpGaD
Gliclazide—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—colon cancer	5.01e-05	0.00108	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—EGFR—colon cancer	4.78e-05	0.00103	CbGpPWpGaD
Gliclazide—ABCC8—Neuronal System—HRAS—colon cancer	4.73e-05	0.00102	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—TP53—colon cancer	4.72e-05	0.00102	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ODC1—colon cancer	4.67e-05	0.00101	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CHST5—colon cancer	4.67e-05	0.00101	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—AKT1—colon cancer	4.6e-05	0.000994	CbGpPWpGaD
Gliclazide—KCNJ11—Neuronal System—HRAS—colon cancer	4.59e-05	0.000991	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—KRAS—colon cancer	4.51e-05	0.000975	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—CTNNB1—colon cancer	4.3e-05	0.000929	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CHST5—colon cancer	4.19e-05	0.000905	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ODC1—colon cancer	4.19e-05	0.000905	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—EP300—colon cancer	4e-05	0.000864	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—EP300—colon cancer	3.92e-05	0.000848	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—SRC—colon cancer	3.89e-05	0.00084	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—HRAS—colon cancer	3.84e-05	0.000829	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—ABCB1—colon cancer	3.82e-05	0.000826	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CHST5—colon cancer	3.82e-05	0.000825	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ODC1—colon cancer	3.82e-05	0.000825	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—SRC—colon cancer	3.81e-05	0.000824	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—TYMS—colon cancer	3.76e-05	0.000812	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—NRAS—colon cancer	3.74e-05	0.000808	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—ABCB1—colon cancer	3.71e-05	0.000801	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—NRAS—colon cancer	3.67e-05	0.000793	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—TYMS—colon cancer	3.64e-05	0.000787	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—TGFB1—colon cancer	3.48e-05	0.000751	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—TGFB1—colon cancer	3.41e-05	0.000737	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—EGFR—colon cancer	3.41e-05	0.000736	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—KRAS—colon cancer	3.22e-05	0.000696	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—KRAS—colon cancer	3.16e-05	0.000682	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—PIK3CA—colon cancer	2.9e-05	0.000627	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—TP53—colon cancer	2.81e-05	0.000607	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—HRAS—colon cancer	2.74e-05	0.000591	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—HRAS—colon cancer	2.68e-05	0.00058	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PPARG—colon cancer	2.66e-05	0.000575	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—ABCB1—colon cancer	2.63e-05	0.000569	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—SRC—colon cancer	2.61e-05	0.000564	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PPARG—colon cancer	2.58e-05	0.000557	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—VEGFA—colon cancer	2.54e-05	0.00055	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—AKT1—colon cancer	2.42e-05	0.000522	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—AKT1—colon cancer	2.37e-05	0.000512	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—TGFB1—colon cancer	2.33e-05	0.000504	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—FGFR3—colon cancer	2.29e-05	0.000496	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—APC—colon cancer	2.11e-05	0.000455	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PTGS2—colon cancer	2.09e-05	0.000452	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PTGS2—colon cancer	2.03e-05	0.000439	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—PIK3CA—colon cancer	1.99e-05	0.000429	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—BRAF—colon cancer	1.98e-05	0.000428	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PPARG—colon cancer	1.93e-05	0.000416	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—EP300—colon cancer	1.74e-05	0.000376	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—colon cancer	1.73e-05	0.000374	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—EP300—colon cancer	1.69e-05	0.000365	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—AKT1—colon cancer	1.62e-05	0.000351	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—colon cancer	1.58e-05	0.000341	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.52e-05	0.000327	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CASP3—colon cancer	1.48e-05	0.000321	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CCND1—colon cancer	1.44e-05	0.000312	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CTNNB1—colon cancer	1.43e-05	0.000309	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CDKN1A—colon cancer	1.4e-05	0.000302	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—EP300—colon cancer	1.38e-05	0.000299	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.36e-05	0.000294	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—SRC—colon cancer	1.35e-05	0.000291	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—EP300—colon cancer	1.33e-05	0.000287	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—VEGFA—colon cancer	1.31e-05	0.000283	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—NRAS—colon cancer	1.3e-05	0.00028	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—SRC—colon cancer	1.29e-05	0.000279	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PIK3CA—colon cancer	1.29e-05	0.000278	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.26e-05	0.000272	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PIK3CA—colon cancer	1.25e-05	0.00027	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—NRAS—colon cancer	1.24e-05	0.000269	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.24e-05	0.000268	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ABCB1—colon cancer	1.23e-05	0.000266	CbGpPWpGaD
Gliclazide—ALB—Metabolism—TYMS—colon cancer	1.21e-05	0.000262	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—TGFB1—colon cancer	1.2e-05	0.00026	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MYC—colon cancer	1.16e-05	0.00025	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TGFB1—colon cancer	1.16e-05	0.00025	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—EGFR—colon cancer	1.13e-05	0.000245	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.13e-05	0.000244	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—KRAS—colon cancer	1.11e-05	0.000241	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ABCB1—colon cancer	1.11e-05	0.000239	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—TYMS—colon cancer	1.09e-05	0.000235	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—KRAS—colon cancer	1.07e-05	0.000231	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—AKT1—colon cancer	1.05e-05	0.000227	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.03e-05	0.000223	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PIK3CA—colon cancer	1.02e-05	0.000221	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—AKT1—colon cancer	1.02e-05	0.00022	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ABCB1—colon cancer	1.01e-05	0.000218	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—TYMS—colon cancer	9.91e-06	0.000214	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—TP53—colon cancer	9.91e-06	0.000214	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PIK3CA—colon cancer	9.84e-06	0.000213	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TP53—colon cancer	9.52e-06	0.000206	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—HRAS—colon cancer	9.48e-06	0.000205	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	9.32e-06	0.000201	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—HRAS—colon cancer	9.1e-06	0.000197	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PPARG—colon cancer	8.58e-06	0.000185	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	8.37e-06	0.000181	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—AKT1—colon cancer	8.37e-06	0.000181	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—AKT1—colon cancer	8.04e-06	0.000174	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PPARG—colon cancer	7.7e-06	0.000166	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	7.63e-06	0.000165	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PPARG—colon cancer	7.02e-06	0.000152	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PTGS2—colon cancer	6.75e-06	0.000146	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PTGS2—colon cancer	6.06e-06	0.000131	CbGpPWpGaD
Gliclazide—ALB—Metabolism—EP300—colon cancer	5.61e-06	0.000121	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PTGS2—colon cancer	5.52e-06	0.000119	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—EP300—colon cancer	5.04e-06	0.000109	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—EP300—colon cancer	4.59e-06	9.93e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PIK3CA—colon cancer	4.15e-06	8.97e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PIK3CA—colon cancer	3.73e-06	8.05e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PIK3CA—colon cancer	3.4e-06	7.34e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—AKT1—colon cancer	3.39e-06	7.33e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—AKT1—colon cancer	3.05e-06	6.58e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—AKT1—colon cancer	2.78e-06	6e-05	CbGpPWpGaD
